Form 4: ARTIVION CEO Sells $529K in Company Stock

Sentiment:

Insider Transaction Report 19 August 2025 11:28 AM

ARTIVION, Inc. President and CEO James P. Mackin sold 12,500 shares of common stock for approximately $529,000 on August 15, 2025, under a pre-arranged trading plan.

Worse than expectedThe President & CEO sold a significant number of shares (12,500 shares totaling approximately $529,000).While conducted under a 10b5-1 plan, insider selling can sometimes be interpreted by investors as a signal of reduced confidence or a desire to take profits, potentially leading to negative sentiment.

Summary

James P. Mackin, President & CEO of ARTIVION, Inc. (AORT), sold 12,500 shares of common stock.
The transaction occurred on August 15, 2025.
The shares were sold at a weighted average price of $42.319 per share, with prices ranging from $42.25 to $42.585.
The total value of the shares sold was approximately $528,987.50.
Following the sale, Mr. Mackin beneficially owns 852,783 shares of ARTIVION common stock.
The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 4

Explanation: The sale of shares by a key executive, even under a pre-arranged plan, can be viewed with slight caution by the market, though it is not indicative of fundamental issues.

Negatives

Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it might suggest a desire to diversify holdings or take profits by a key executive.

Risks

Potential negative market perception due to insider selling, which could lead to short-term share price volatility.

Future Outlook

Industry Context

Insider transactions are common across all industries and do not inherently relate to broader industry trends unless there is a widespread pattern of insider selling across the sector. This specific filing does not provide industry-wide context.

Stakeholder Impact

Shareholders: May interpret the sale as a signal, potentially impacting short-term sentiment or share price.

Key Dates

Date	Description
08/15/2025	Date of common stock transaction by James P. Mackin.
08/19/2025	Date the Form 4 filing was signed and submitted.

Recommendation

hold

While the President & CEO sold shares, the transaction was conducted under a Rule 10b5-1 pre-arranged trading plan, which suggests it was not based on new material non-public information. This single transaction, representing a small fraction of the CEO's total beneficial ownership (852,783 shares remaining), does not fundamentally alter the investment thesis for ARTIVION, Inc. without further context or a pattern of significant insider selling.

Keywords

ARTIVION, AORT, Insider Sale, James P. Mackin, CEO, Stock Transaction, Form 4, SEC Filing, 10b5-1 Plan, Medical Devices

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.